Empliciti (elotuzumab) for the Treatment of Multiple Myeloma

Empliciti in combination with pomalidomide and low-dose dexamethasone was approved by the EMA for the treatment of patients with relapsed and refractory multiple myeloma in August 2019. Image courtesy of



  • Empliciti
  • Empliciti
  • Empliciti